![Michael Gilman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Gilman
Directeur/Membre du Conseil chez
SCHOLAR ROCK HOLDING CORPORATION
Fortune : 3 M $ au 31/05/2026
Profil
Michael Gilman was the founder of Stromedix, Inc. (2006), where the title held was Chief Executive Officer in 2012.
Dr. Gilman was the founder of X4 Pharmaceuticals, Inc. (2014), holding the title of Director.
Dr. Gilman is the founder of Padlock Therapeutics, Inc. (2014), serving as President, Director & Secretary.
Dr. Gilman was the founder of Obsidian Therapeutics, Inc. (2015), where the title held was Chief Executive Officer & Director from 2015 to 2019.
Dr. Gilman is currently Chief Executive Officer & Director at Arrakis Therapeutics, Inc. since 2019.
Dr. Gilman is a Director at Scholar Rock, Inc. since 2013.
Dr. Gilman is an Independent Director at Scholar Rock Holding Corp.
since 2013.
Dr. Gilman is a Scientific Advisor at FutuRx Ltd. Dr. Gilman was Director at EPIX Pharmaceuticals, Inc. Dr. Gilman was Director at Via Science, Inc. Dr. Gilman was Chief Scientific Officer & Executive VP at ARIAD Pharmaceuticals, Inc. from 1994 to 1999.
Dr. Gilman was Senior Vice President-Early-Stage Pipeline at Biogen, Inc. from 2012 to 2013.
Dr. Gilman was Executive Vice President-Research at Biogen, Inc. from 1999 to 2005.
Dr. Gilman completed undergraduate education at Massachusetts Institute of Technology in 1976.
Dr. Gilman earned a doctorate from the University of California, Berkeley in 1983.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/06/2026 | 62 055 ( 0,05 % ) | 3 M $ | 31/05/2026 |
Postes actifs de Michael Gilman
| Sociétés | Poste | Début |
|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Directeur/Membre du Conseil | 01/11/2013 |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Develops medicines targeting protein-arginine deiminases | Fondateur | 01/01/2014 |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Directeur/Membre du Conseil | 01/11/2013 |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops RNA-targeted small molecules on neurologic diseases, cancer and rare genetic diseases | Directeur Général | 01/10/2016 |
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx invests in companies located in Israel. The firm focuses on sectors such as health technology and technology services with an investment size of ILS 3 million. It participates in seed stage transactions and also makes follow on investment. | Consultant / Advisor | - |
Anciens postes connus de Michael Gilman
| Sociétés | Poste | Fin |
|---|---|---|
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops TIL cell therapies for the treatment of patients with solid tumors | Fondateur | 01/04/2019 |
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops and distributes oral small molecule CXCR4 antagonists | Fondateur | 01/03/2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01/06/2013 |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Fondateur | 01/03/2012 |
| ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Formation de Michael Gilman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
92
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops pharmaceuticals | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Health Technology |
X4 Pharmaceuticals, Inc. /Old/
X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops and distributes oral small molecule CXCR4 antagonists | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Via Science, Inc.
 Via Science, Inc. Packaged SoftwareTechnology Services Operates as a patented, automated analytics platform to solve high-value complex problems | Technology Services |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Develops medicines targeting protein-arginine deiminases | Health Technology |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx invests in companies located in Israel. The firm focuses on sectors such as health technology and technology services with an investment size of ILS 3 million. It participates in seed stage transactions and also makes follow on investment. | Finance |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops TIL cell therapies for the treatment of patients with solid tumors | Health Technology |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops RNA-targeted small molecules on neurologic diseases, cancer and rare genetic diseases | Health Technology |
Scholar Rock Holding Corp.
 Scholar Rock Holding Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focused on the discovery, development and delivery medicines for neuromuscular, cardiometabolic disorders, cancer, fibrosis and iron-restricted anemia | Health Technology |
